The estimated Net Worth of Sanjiv Patel is at least $7.25 Milión dollars as of 25 July 2024. Dr Patel owns over 86,706 units of Relay Therapeutics stock worth over $6,230,007 and over the last 4 years he sold RLAY stock worth over $0. In addition, he makes $1,016,803 as CEO a Pres & Director at Relay Therapeutics.
Dr has made over 8 trades of the Relay Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 86,706 units of RLAY stock worth $436,998 on 25 July 2024.
The largest trade he's ever made was exercising 86,706 units of Relay Therapeutics stock on 25 July 2024 worth over $436,998. On average, Dr trades about 24,873 units every 81 days since 2020. As of 25 July 2024 he still owns at least 802,836 units of Relay Therapeutics stock.
You can see the complete history of Dr Patel stock trades at the bottom of the page.
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS is the CEO, Pres & Director at Relay Therapeutics.
As the CEO a Pres & Director of Relay Therapeutics, the total compensation of Dr MBBS at Relay Therapeutics is $1,016,803. There are no executives at Relay Therapeutics getting paid more.
Dr MBBS is 47, he's been the CEO a Pres & Director of Relay Therapeutics since . There are 3 older and 1 younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics, Inc. is Dr. Mark Murcko Ph.D., 61, who is the Co-Founder & Director.
Sanjiv's mailing address filed with the SEC is C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Relay Therapeutics have traded over $234,228,237 worth of Relay Therapeutics stock and bought 110,000 units worth $2,200,000 . The most active insiders traders include Rock Ventures Iii, L.P.Thir..., Sanjiv Patel a Donald A Bergstrom. On average, Relay Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $406,570. The most recent stock trade was executed by Thomas Catinazzo on 29 July 2024, trading 10,780 units of RLAY stock currently worth $92,277.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics executives and other stock owners filed with the SEC include: